STAMINA & STRENGTH: Worth Watching Stocks: Chimera Investment Corporation (NYSE:CIM) , Nu Skin Enterprises, Inc.

FREE TRAFFIC

FREE Viral marketing tool generates FREE traffic / visitors to your website automatically. Click here to find out more.


Thursday, March 16, 2017

Worth Watching Stocks: Chimera Investment Corporation (NYSE:CIM) , Nu Skin Enterprises, Inc.

   
On 3/15/2017, Shares of Chimera Investment Corporation (NYSE:CIM) closed at $19.59 in last trading day. After noting the initial trading entry at $19.29, it reached to a day’s high of $19.68 and moved to a day’s low of $19.27. The recent daily volume was 2.41 million as contrast to it’s an average volume of 1.41 million.
Technical Indicators:
The last close of the Chimera Investment Corporation stock reflects that it traded up +5.42% from its 50-day moving average of $18.58. The stock traded above +15.08% to its 200-day MA of $17.02. Furthermore, it moved higher lower -0.46% from its 52-week high of $19.68 and +48.63% up down from $13.18, which is 52-week low of the stock.
Chimera Investment Corporation’s (CIM) moved with shift of 3.71% in the past week. Over the last three months, the shares of the company have changed 16.49% and performed 30.58% over the last six months. The stock currently has Monthly Volatility of 1.55% and Weekly Volatility of 1.82%.
Chimera Investment Corporation operates as a real estate investment trust in the United States. The company, through its subsidiaries, invests in residential mortgage-backed securities (RMBS), residential mortgage loans, commercial mortgage loans, real estate-related securities, and various other asset classes. The company has elected to be taxed as a real estate investment trust. As a result, it would not be subject to corporate income tax on that portion of its net income that is distributed to shareholders. Chimera Investment Corporation was founded in 2007 and is based in New York, New York.
Nu Skin Enterprises, Inc. (NYSE:NUS) finalized the last transaction at value of $51.82, with a daily change of +2.78% or +1.40 points. The company maintained volume of 1.1 million shares. In past trading day, the stock hit the maximum price of $51.99 and touched to minimum value of $50.39. It has a market cap of $ 2.72B.
  
Technical Indicators:
As of last trade close, the stock is trading upside downside -21.53% from its one year high of $66.04 and moved +43.55% downward upward from $36.10, which is one year low of the stock.
The stock traded above +1.28% from its 50-day moving average of $51.17. Furthermore, the stock moved down -5.61% to its 200-day MA of $ 54.90.
During the last month, Nu Skin Enterprises, Inc.’s (NUS) has changed -2.39% and performed -7.86% over the last 6 months. The mean rating score for this stock is at 2.40. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 2.80% in recent month and observed Weekly Volatility of 2.44%.
Nu Skin Enterprises, Inc. develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC Transformation anti-aging skin care systems; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, and LifePak nutritional supplements, as well as other anti-aging nutritional solutions and weight management products. In addition, it is involved in the research and product development of aging, such as the influence of certain ingredients on gene expression. The company sells its products directly as well as through distributors, and its retail stores and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.


find original article here

No comments:

Post a Comment